TESSERA THERAPEUTICS
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
TESSERA THERAPEUTICS
Industry:
Biopharma Biotechnology Genetics Life Science Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tesseratherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
531.76 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Tag Manager Google Analytics LetsEncrypt SSL By Default Global Site Tag Organization Schema
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Beyond Air
Beyond Air is a biotechnology company that focuses on the development of drugs for the treatment of lung infections.
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Ascidian Therapeutics
Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Element Biosciences
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical stage biotechnology company.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Noubar Afeyan Co-Founder & Board Member @ Tessera Therapeutics
Co-Founder & Board Member
2018-01-01
Nathaniel Roquet Director of Reagent Foundry @ Tessera Therapeutics
Director of Reagent Foundry
2022-05-01
Jacob Rubens Co-Founder & Chief Scientific Officer @ Tessera Therapeutics
Co-Founder & Chief Scientific Officer
2018-01-01
Howard Liang President and CFO @ Tessera Therapeutics
President and CFO
2021-07-01
Iain McFadyen Chief Data Officer @ Tessera Therapeutics
Chief Data Officer
2021-10-01
Geoffrey von Maltzahn Co-Founder, Chief Executive Officer & Board member @ Tessera Therapeutics
Co-Founder, Chief Executive Officer & Board member
2018-07-01
Founder
Investors List
Longevity Vision Fund
Longevity Vision Fund investment in Series C - Tessera Therapeutics
SALT Fund
SALT Fund investment in Series C - Tessera Therapeutics
Hanwha Impact Partners
Hanwha Impact Partners investment in Series C - Tessera Therapeutics
March Capital
March Capital investment in Series C - Tessera Therapeutics
Alaska Permanent Fund
Alaska Permanent Fund investment in Series C - Tessera Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Tessera Therapeutics
Altitude Life Science Ventures
Altitude Life Science Ventures investment in Series C - Tessera Therapeutics
SoftBank Vision Fund
SoftBank Vision Fund investment in Series C - Tessera Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series C - Tessera Therapeutics
Artis Ventures (AV)
Artis Ventures (AV) investment in Series C - Tessera Therapeutics
Official Site Inspections
http://www.tesseratherapeutics.com Semrush global rank: 1.78 M Semrush visits lastest month: 12.63 K
- Host name: 413450.cloudwaysapps.com
- IP address: 167.172.146.87
- Location: North Bergen United States
- Latitude: 40.793
- Longitude: -74.0247
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07047
Tesseratherapeutics.com lookup results from whois.networksolutions.com server:
- Domain created: 14th-Nov-2019
- Domain updated: 13th-Aug-2024
- Domain expires: 14th-Nov-2027 2 Years, 225 Days left
- Website age: 5 Years, 139 Days
- Registrar Domain ID: 2455346239_DOMAIN_COM-VRSN
- Registrar Url: http://networksolutions.com
- Registrar WHOIS Server: whois.networksolutions.com
- Registrar Abuse Contact Email: domain.operations@web.com
- Registrar Abuse Contact Phone: +1.8777228662
- Name server:
- NS51.WORLDNIC.COM
- NS52.WORLDNIC.COM
More informations about "Tessera Therapeutics"
Tessera Therapeutics - Crunchbase Company Profile
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the …See details»
Careers - Tessera Therapeutics
Our dedicated team is pioneering Gene Writing™ - a new genome engineering technology that writes in the code of life. We are looking for creative thinkers who can help fuel this ambitious …See details»
Tessera Therapeutics - LinkedIn
Tessera Therapeutics is a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, with the aim to unlock broad ...See details»
Tessera Therapeutics, Inc. Company Profile | Cambridge, MA ...
Find company research, competitor information, contact details & financial data for Tessera Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Focus Areas - Tessera Therapeutics
At Tessera, we are advancing our Gene Writing™ technology and proprietary LNP delivery system to alter the human genome and effect precise, durable therapeutic change to cure even the most challenging genetic diseases.See details»
Tessera Therapeutics 2025 Company Profile | PitchBook
Information on valuation, funding, cap tables, investors, and executives for Tessera Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Raised $532M Funding from 24 investors - Tracxn
6 days ago Tessera Therapeutics has raised a total funding of $532M over 3 rounds from 24 investors. Investors include Foresite Capital, Flagship Pioneering and 22 others. Their latest …See details»
Tessera Therapeutics - Company Profile - Tracxn
Feb 27, 2025 Tessera Therapeutics - Provider of new genome engineering technology for treating multiple diseases. Raised a total funding of $532M over 3 rounds from 24 investors. …See details»
Tessera Therapeutics Overview | SignalHire Company Profile
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large …See details»
Tessera Therapeutics (USA) Funding: $531.8M
Mar 11, 2025 Tessera Therapeutics is pioneering Gene Writing - a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their...See details»
Tessera Therapeutics - Flagship Pioneering
Latest News from Tessera Therapeutics. Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer 06.02.2022; Tessera Therapeutics …See details»
Company: Tessera Therapeutics - CRISPR Medicine
Tessera Therapeutics is a Flagship Pioneering founded start-up company that focuses on a novel gene-editing technology known as gene writing. Gene writing is based on using mobile genetic …See details»
Biology - Tessera Therapeutics
In recent years, we’ve made extraordinary leaps in genetic medicine, with two pillar technologies emerging: gene therapy and gene editing. While these methods are offering potential cures for …See details»
Tessera Therapeutics - VentureRadar
Auto Analyst Score: 68 | tesseratherapeutics.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times …See details»
Leading Gene Writing Company Tessera Therapeutics Announces …
Jul 14, 2021 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, announced …See details»
Who Owns Tessera Therapeutics – CanvasBusinessModel.com
Oct 2, 2024 [cbm_blg_rlnkng]Discover the enigmatic ownership structure of Tessera Therapeutics, a cutting-edge biotechnology company revolutionizing gene writing. As rumors …See details»
Tessera Therapeutics Highlights Advances Across In Vivo Programs …
Dec 9, 2024 In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs) using Gene Writers encapsulated in proprietary lipid nanoparticles (LNPs) targeting …See details»
News - Tessera Therapeutics
May 11, 2024 12.18.2024 | Press Release Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease By Tessera Therapeutics …See details»
New study results reinforce Tagrisso as the backbone therapy for …
3 days ago New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy …See details»
Eterna Therapeutics Changes Name to Ernexa Therapeutics to
2 days ago Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product developmentSee details»